Ars Technica AI
Thursday, May 28, 2026
Beth Mole
Bad cholesterol slashed 62% by single dose of gene-editing drug in small trial
AI-Powered Summary
Generated by callmor.ai's AI to save you time
Summary
The interim Phase I trial data was only from 35 people, but results look good so far.
Original Source
This article was originally published by Ars Technica AI. Read the full original article for complete details, images, and author commentary.
Read Original ArticleWant AI working for your business?
callmor.ai builds AI products that automate your operations 24/7.
Explore AI Products